GenVec Inc. Expands TNFerade Phase II Pancreatic Cancer Study Into Phase II/III Trial; Company Secures $30 Million

GAITHERSBURG, Md.--(BUSINESS WIRE)--March 15, 2006--GenVec, Inc. (Nasdaq:GNVC) today announced that it received clearance from the U.S. Food and Drug Administration (FDA) to expand its current Phase II clinical trial with TNFerade in locally advanced pancreatic cancer into a Phase II/III trial with a 12-month survival endpoint. Targeted enrollment will be expanded from 74 to 330 patients. The expanded Phase II/III trial will include additional study sites outside the United States.
MORE ON THIS TOPIC